Harmonized and Pooled Database, Named PRIME.
PRIME
Potentially Modifiable Ventilation Factors Associated With Outcome in Neurocritical Care vs Non-Neurocritical Care Patients - Rational and Protocol for a Patient-Level Analysis of PRoVENT, PRoVENT-iMiC and ENIO (PRIME)
1 other identifier
observational
3,270
1 country
1
Brief Summary
We merged the dataset of three large observational studies of invasive ventilation in critically ill patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
July 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 26, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedSeptember 19, 2024
September 1, 2024
7 months
July 22, 2024
September 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ICU morality
any mortality occurred during ICU stay
ICU stay, anticipated average 15 days
Secondary Outcomes (1)
Mechanical Power
During the first 7 days of invasive ventilation
Study Arms (1)
Patients receiving invasive ventilation
Patients receiving invasive ventilation, included in PRoVENT, PRoVENT-iMiC, and ENIO
Interventions
Invasive ventilation and respiratory support
Eligibility Criteria
PROVENT, PROVENT-iMiC and ENIO included various types of patients, receiving ventilation for different reasons. For this first analysis we will select patients receiving invasive ventilation for acute brain injury.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amsterdam, Netherlands
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marcus J Schultz, Prof
Amsterdam UMC
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr
Study Record Dates
First Submitted
July 22, 2024
First Posted
September 19, 2024
Study Start
January 1, 2024
Primary Completion
July 26, 2024
Study Completion
July 26, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ANALYTIC CODE
- Time Frame
- After our first pubblication (next six months) and they will remain available for ever
- Access Criteria
- For this, interested investigators will have to provide a detailed analysis plan, containing a testable hypothesis, clearly described endpoints and an analysis plan. After approval, investigators will be provided with a mock database that will allow them to write an analysis script in R. PROVE network investigators will then run the script on the PRIME database and provide the investigators with the results. Any publication from an additional analysis must follow the rules for publication denoted by the PROVE network
Notably, after this initial analysis of PRIME, the database is available for post-hoc analysis.